- Home
- APLT vs RENB Comparison
APLT vs RENB Comparison
Compare APLT & RENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- RENB
- Stock Information
- Founded
- APLT 2016
- RENB 2011
- Country
- APLT United States
- RENB United States
- Employees
- APLT N/A
- RENB N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- RENB Biotechnology: Pharmaceutical Preparations
- Sector
- APLT Health Care
- RENB Health Care
- Exchange
- APLT Nasdaq
- RENB Nasdaq
- Market Cap
- APLT 128.0M
- RENB 121.3M
- IPO Year
- APLT 2019
- RENB N/A
- Fundamental
- Price
- APLT $0.65
- RENB $0.71
- Analyst Decision
- APLT Buy
- RENB
- Analyst Count
- APLT 7
- RENB 0
- Target Price
- APLT $6.10
- RENB N/A
- AVG Volume (30 Days)
- APLT 7.5M
- RENB 1.8M
- Earning Date
- APLT 03-05-2025
- RENB 02-12-2025
- Dividend Yield
- APLT N/A
- RENB N/A
- EPS Growth
- APLT N/A
- RENB N/A
- EPS
- APLT N/A
- RENB N/A
- Revenue
- APLT N/A
- RENB N/A
- Revenue This Year
- APLT N/A
- RENB N/A
- Revenue Next Year
- APLT $2,622.90
- RENB N/A
- P/E Ratio
- APLT N/A
- RENB N/A
- Revenue Growth
- APLT N/A
- RENB N/A
- 52 Week Low
- APLT $0.60
- RENB $0.40
- 52 Week High
- APLT $10.62
- RENB $5.25
- Technical
- Relative Strength Index (RSI)
- APLT 20.60
- RENB 38.93
- Support Level
- APLT $0.60
- RENB $0.74
- Resistance Level
- APLT $0.74
- RENB $0.94
- Average True Range (ATR)
- APLT 0.09
- RENB 0.14
- MACD
- APLT 0.21
- RENB -0.04
- Stochastic Oscillator
- APLT 13.53
- RENB 1.21
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About RENB Renovaro Biosciences Inc.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.